Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 8/2016

01-08-2016 | Original Article

Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive

Authors: S. Caruso, M. Iraci, S. Cianci, V. Fava, E. Casella, A. Cianci

Published in: Journal of Endocrinological Investigation | Issue 8/2016

Login to get access

Abstract

Purpose

To evaluate the effects of a continuous regimen combined oral contraceptive (COC) containing 2 mg dienogest and 30 µg ethinyl estradiol (DNG/EE) compared to a 21/7 regimen on the quality of life (QoL) and sexual function in women affected by endometriosis-associated pelvic pain.

Methods

Sixty-three women constituted the Study group treated with DNG/EE COC continuous regimen; 33 women were given DNG/EE COC in a 21/7 regimen. To define the endometriosis-associated pelvic pain, the Visual Analogic Scale was used. The Short Form-36, Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess QoL, sexual function and sexual distress, respectively. The study included two follow-ups.

Results

At 3 and 6 months of treatment there was an improvement in pain of the Study group (p < 0.001). The Control group underwent pain improvement at the second follow-up (p < 0.05). At the first and the second follow-ups, the Study group reported QoL improvements in all categories (p < 0.001). The Control group reported QoL improvements in all categories at the second follow-up (p < 0.05). At the first and the second follow-ups of the Study group, the FSFI total score had risen (p < 0.001), and the FSDS score had dropped (p < 0.001). An improvement of the FSFI score and a reduction of the FSDS score of the Control group was observed at the second follow-up (p < 0.001), but not at the first follow-up (p = NS).

Conclusions

Women on DNG/EE COC continuous regimen reported a reduction of endometriosis-associated pelvic pain and there was an improvement of their sexual activity and their QoL that was better than the DNG/EE 21/7 conventional regimen.
Literature
1.
Huntington A, Gilmour JA (2005) A life shaped by pain: women and endometriosis. J Clin Nurs 14:1124–1132CrossRefPubMed
2.
3.
Nnoaham KE, Sivananthan S, Hummelshoj L, Jenkinson C, Webster P, Kennedy SH, Zondervan KT (2009) Multi-centre studies of the global impact of endometriosis and the predictive value of associated symptoms. J Endometr 1:36–45PubMedPubMedCentral
4.
Sepulcri RP, do Amarai VF (2009) Depressive symptoms, anxiety, and quality of life in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 142:53–56CrossRef
5.
Hummelshoj L, De Graaff A, Dunselman G, Vercellini P (2014) Let’s talk about sex and endometriosis. J Fam Plann Reprod Health Care 40:8–10CrossRefPubMed
6.
Hyun Shin JA, Howard FM (2011) Management of chronic pelvic pain. Curr Pain Headache Rep 15:377–385CrossRef
7.
Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, Stratton P (2008) Differences in characteristics of 1.000 women with endometriosis based on extent of disease. Fertil Steril 89:538–545CrossRefPubMed
8.
Rogers PA, D’Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, Montgomery GW, Rombauts L, Salamonsen LA, Zondervan KT (2009) Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci 16:335–346CrossRefPubMedPubMedCentral
9.
Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E, ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20:2698–2704CrossRefPubMed
10.
Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W, European Society of Human Reproduction and Embryology (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29:400–412CrossRefPubMed
11.
Vercellini P, Viganò P, Somigliana E, Fedele L (2014) Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 10:261–275CrossRefPubMed
12.
Jeng CJ, Chuang L, Shen J (2014) A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother 15:767–773CrossRefPubMed
13.
Leone Roberti Maggiore U, Remorgida V, Scala C, Tafi E, Venturini PL, Ferrero S (2014) Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand 93:239–247CrossRefPubMed
14.
Edelman A, Micks E, Gallo MF, Jensen JT, Grimes DA (2014) Continuous or extended cycle versus cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 7:CD004695PubMed
15.
Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG (2005) Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate. Fertil Steril 84:1375–1387CrossRefPubMed
16.
Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R (2003) Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80:560–563CrossRefPubMed
17.
Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakult T (2012) Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain; a randomized comparative trial. Gynecol Obstet Invest 74:151–156CrossRefPubMed
18.
Dmitrovic R, Kunselman A, Legro R (2012) Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 119:1143–1150CrossRefPubMedPubMedCentral
19.
Coffee AL, Sulak PJ, Kuehl TJ (2007) Extended-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 75:444–449CrossRefPubMed
20.
Birtch RL, Olatunbosun OA, Pierson RA (2006) Ovarian follicular dynamics during conventional versus continuous oral contraceptive use. Contraception 73:235–243CrossRefPubMed
21.
Allen C, Hopewell S, Prentice A, Gregory D (2009) Nonsteroidal antiinflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2:CD004753PubMed
22.
The Practice Committee of the American Society for Reproductive Medicine (2014) Treatment of pelvic pain associated with endometriosis. Fertil Steril 101:927–935CrossRef
23.
Bizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, Salvatore S, Candiani M, Venturini PL, Ferrero S (2014) Dienogest in the treatment of endometriosis. Expert Opin Pharmacother 15:1889–1902CrossRefPubMed
24.
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008) Classification and pharmacology of progestins. Maturitas 61:171–180CrossRefPubMed
25.
Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B (2012) Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 52:1704–1713CrossRefPubMed
26.
Sitruk-Ware R, Nath A (2010) The use of newer progestins for contraception. Contraception 82:410–417CrossRefPubMed
27.
Grandi G, Xholli A, Napolitano A, Palma F, Cagnacci A (2015) Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci 22:626–632CrossRefPubMed
28.
Gallagher EJ, Liebman M, Bijur PE (2001) Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 38:633–638CrossRefPubMed
29.
Ware JE, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, Brazier J, Bullinger M, Kaasa S, Leplège A, Prieto L, Sullivan M (1998) The factor structure of the SF-36 Health Survey in 10 countries: results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 51:1159–1165CrossRefPubMed
30.
Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW (2004) Revised definitions of women’s sexual dysfunction. J Sex Med 1:40–48CrossRefPubMed
31.
Nappi RE, Albani F, Vaccaro P, Gardella B, Salonia A, Chiovato L, Spinillo A, Polatti F (2008) Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol 24:214–219CrossRefPubMed
32.
Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J (2002) The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal in distress women. J Sex Marital Ther 28:317–330CrossRefPubMed
33.
Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M (2015) Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update 21:136–152CrossRefPubMed
34.
Borghese B, Sibiude J, Santulli P, Lafay Pillet MC, Marcellin L, Brosens I, Chapron C (2015) Low birth weight is strongly associated with the risk of deep infiltrating endometriosis: results of a 743 case–control study. PLoS One 10:e0117387CrossRefPubMedPubMedCentral
35.
Di Donato N, Montanari G, Benfenati A, Leonardi D, Bertoldo V, Monti G, Raimondo D, Seracchioli R (2014) Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol 181:289–293CrossRefPubMed
36.
Vercellini P, Consonni D, Barbara G, Buggio L, Frattaruolo MP, Somigliana E (2014) Adenomyosis and reproductive performance after surgery for rectovaginal and colorectal endometriosis: a systematic review and meta-analysis. Reprod Biomed Online 28:704–713CrossRefPubMed
37.
Koga K, Takamura M, Fujii T, Osuga Y (2015) Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril 104:793–801CrossRefPubMed
38.
Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y (2014) Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 30:644–648CrossRefPubMed
39.
Ferrari S, Persico P, Di Puppo F, Vigano P, Tandoi I, Garavaglia E, Giardina P, Mezzi G, Candiani M (2012) Continuous low-dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal endoscopic ultrasonography. Acta Obstet Gynecol Scand 91:699–703CrossRefPubMed
40.
Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A (2015) Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest 38:1211–1218CrossRefPubMed
41.
Nakamura M, Katsuki Y, Shibutani Y, Oikawa T (1999) Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 386:33–40CrossRefPubMed
42.
Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Lange E, Mellinger U, Palombo-Kinne E, Kuhl H (2011) Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 84:133–143CrossRefPubMed
43.
Hee L, Kettner LO, Vejtorp M (2013) Continuous use of oral contraceptives: an overview of effects and side-effects. Acta Obstet Gynecol Scand 92:125–136CrossRefPubMed
44.
Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD (2010) Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception 82:497–502CrossRefPubMed
45.
Nappi RE, Kaunitz AM, Bitzer J (2015) Extended regimen combined oral contraception: a review of evolving concepts and acceptance by women and clinicians. Eur J Contracept Reprod Health Care 17:1–9
46.
Panicker S, Mann S, Shawe J, Stephenson J (2014) Evolution of extended use of the combined oral contraceptive pill. J Fam Plann Reprod Health Care 40:133–141CrossRefPubMed
47.
48.
Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N (2009) Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril 91:323–329CrossRef
49.
Laufer MR (2008) Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest 66(Suppl 1):19–27CrossRefPubMed
50.
Vercellini P, Frattaruolo MP, Somigliana E, Jones GL, Consonni D, Alberico D, Fedele L (2013) Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod 28:1221–1230CrossRefPubMed
51.
McCormack PL (2010) Dienogest: a review of its use in the treatment of endometriosis. Drugs 70:2073–2088CrossRefPubMed
52.
Caruso S, Malandrino C, Cicero C, Ciancio F, Cariola M, Cianci A (2013) Quality of sexual life of women on oral contraceptive continued-regimen: pilot study. J Sex Med 10:460–466CrossRefPubMed
53.
Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA (2005) Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 3:CD004695PubMed
54.
Sauer U, Mann S, Brima N, Stephenson J (2013) Offering extended use of the combined contraceptive pill: a survey of specialist family planning services. Int J Womens Health 5:613–617CrossRefPubMedPubMedCentral
Metadata
Title
Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive
Authors
S. Caruso
M. Iraci
S. Cianci
V. Fava
E. Casella
A. Cianci
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 8/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0460-6

Other articles of this Issue 8/2016

Journal of Endocrinological Investigation 8/2016 Go to the issue

Original Article

Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls

Endocrinology & Art

Hermaphroditism in Leonardo da Vinci’s Drawing “Angel in the Flesh” (1513–1515)

Letter to the Editor

Absence of TERT promoter mutations in pituitary adenomas

Consensus Statement

Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB)

Review

Endocrine dysfunction in hereditary hemochromatosis

Original Article

The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits